• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

加速药物合作组织精神分裂症项目中的数字健康技术

Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program.

作者信息

Wigman Johanna T W, Ching Ann Ee, Chung Yoonho, Eichi Habiballah Rahimi, Lane Erlend, Langholm Carsten, Vaidyam Aditya, Byun Andrew Jin Soo, Haidar Anastasia, Hartmann Jessica, Nunez Angela, Dwyer Dominic, Nasarudin Adibah Amani, Borders Owen, Scott Isabelle, Tamayo Zailyn, Matneja Priya, Cho Kang-Ik, Addington Jean, Alameda Luis K, Arango Celso, Breitborde Nicholas J K, Broome Matthew R, Cadenhead Kristin S, Calkins Monica E, Chen Eric Yu Hai, Choi Jimmy, Conus Philippe, Corcoran Cheryl M, Cornblatt Barbara A, Diaz-Caneja Covadonga M, Ellman Lauren M, Fusar-Poli Paolo, Gaspar Pablo A, Gerber Carla, Glenthøj Louise Birkedal, Horton Leslie E, Hui Christy Lai Ming, Kambeitz Joseph, Kambeitz-Ilankovic Lana, Keshavan Matcheri S, Kim Sung-Wan, Koutsouleris Nikolaos, Langbein Kerstin, Mamah Daniel, Mathalon Daniel H, Mittal Vijay A, Nordentoft Merete, Pearlson Godfrey D, Perez Jesus, Perkins Diana O, Powers Albert R, Rogers Jack, Sabb Fred W, Schiffman Jason, Shah Jai L, Silverstein Steven M, Smesny Stefan, Yassin Walid, Stone William S, Strauss Gregory P, Thompson Judy L, Upthegrove Rachel, Verma Swapna, Wang Jijun, Wolf Daniel H, Wolff Phillip, Rowland Laura M, D'Alfonso Simon, Pasternak Ofer, Bouix Sylvain, McGorry Patrick D, Kahn Rene S, Kane John M, Bearden Carrie E, Woods Scott W, Shenton Martha E, Nelson Barnaby, Baker Justin T, Torous John

机构信息

University of Groningen, University Medical Center Groningen, Department of Psychiatry, Interdisciplinary Centre of Psychopathology and Emotion regulation, Groningen, The Netherlands.

Centre for Youth Mental Health, The University of Melbourne, Parkville, VIC, Australia.

出版信息

Schizophrenia (Heidelb). 2025 Jun 3;11(1):83. doi: 10.1038/s41537-025-00599-w.

DOI:10.1038/s41537-025-00599-w
PMID:40461469
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12134270/
Abstract

Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach to explore the nature of CHR and may help to improve personalized risk prediction. Specifically, digital data enable detailed mapping of experiences, moods and behaviors during longer periods of time (e.g., weeks, months) and offer more insight into patterns over time at the individual level across their routine daily life. However, while novel digital health technologies open up many new avenues of research, they also come with specific challenges, including replicability of results and the adherence of participants. This paper outlines the design of the digital component of the Accelerating Medicines Partnership® Schizophrenia Program (AMP SCZ) project, a large international collaborative project that follows individuals at CHR for psychosis over a period of two years. The digital component comprises one-year smartphone-based digital phenotyping and actigraphy. Smartphone-based digital phenotyping includes 30-item short daily self-report surveys and voice diaries as well as passive data capture (geolocation, on/off screen state, and accelerometer). Actigraphy data are collected via an Axivity wristwatch. The aim of this paper is to describe the design and the three goals of the digital measures used in AMP SCZ to: (i) better understand the symptoms, real-life experiences, and behaviors of those at CHR for psychosis, (ii) improve the prediction of transition to psychosis and other health outcomes in this population based on digital phenotyping and, (iii) serve as an example for replicable and ethical research across geographically diverse regions and cultures. Accordingly, we describe the rationale, protocol and implementation of these digital components of the AMP SCZ project. **Link to video interview: https://vimeo.com/1060935583 *.

摘要

尽管荟萃分析研究表明,处于精神病临床高危(CHR)状态的人群中,有25%-33%会在三年内发展为首次精神病发作,但在个体层面评估转化风险方面,我们了解得还较少。数字表型分析提供了一种探索CHR本质的新方法,可能有助于改善个性化风险预测。具体而言,数字数据能够详细描绘较长时间段(如数周、数月)内的经历、情绪和行为,并能更深入地洞察个体在日常生活中的长期模式。然而,尽管新型数字健康技术开辟了许多新的研究途径,但它们也带来了一些特定的挑战,包括结果的可重复性和参与者的依从性。本文概述了加速药物合作组织精神分裂症项目(AMP SCZ)数字部分的设计,该项目是一个大型国际合作项目,对处于CHR状态的个体进行为期两年的跟踪研究。数字部分包括为期一年的基于智能手机的数字表型分析和活动记录仪监测。基于智能手机的数字表型分析包括每日30项简短的自我报告调查、语音日记以及被动数据捕获(地理位置、屏幕开关状态和加速度计)。活动记录仪数据通过Axivity手表收集。本文的目的是描述AMP SCZ中使用的数字测量方法的设计及其三个目标:(i)更好地了解处于CHR状态的人群的症状、现实生活经历和行为;(ii)基于数字表型分析改善对该人群向精神病及其他健康结局转化的预测;(iii)为跨地域不同地区和文化的可重复且符合伦理的研究提供范例。因此,我们描述了AMP SCZ项目这些数字部分的基本原理、方案和实施情况。**视频访谈链接:https://vimeo.com/1060935583 *

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0477/12134270/cc9541fe27d8/41537_2025_599_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0477/12134270/cc9541fe27d8/41537_2025_599_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0477/12134270/cc9541fe27d8/41537_2025_599_Fig1_HTML.jpg

相似文献

1
Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目中的数字健康技术
Schizophrenia (Heidelb). 2025 Jun 3;11(1):83. doi: 10.1038/s41537-025-00599-w.
2
Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.加速药物研发合作组织精神分裂症项目(AMP® SCZ):精神分裂症前驱症状全球最大前瞻性队列研究的基本原理和研究设计。
Schizophr Bull. 2024 Apr 30;50(3):496-512. doi: 10.1093/schbul/sbae011.
3
Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目的数据分析策略
Schizophrenia (Heidelb). 2025 Apr 3;11(1):53. doi: 10.1038/s41537-025-00561-w.
4
The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目的磁共振神经成像方案。
Schizophrenia (Heidelb). 2025 Apr 2;11(1):52. doi: 10.1038/s41537-025-00581-6.
5
Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program.加速药物合作组织精神分裂症项目中的样本确定与临床结局指标
Schizophrenia (Heidelb). 2025 Apr 3;11(1):54. doi: 10.1038/s41537-025-00556-7.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Cognitive assessment in the Accelerating Medicines Partnership® Schizophrenia Program: harmonization priorities and strategies in a diverse international sample.加速药物合作组织精神分裂症项目中的认知评估:不同国际样本中的协调重点与策略
Schizophrenia (Heidelb). 2025 Mar 24;11(1):49. doi: 10.1038/s41537-025-00578-1.
8
Kenya Psychosis-Risk Outcomes Study (KePROS): Development of an Accelerated Medicine Partnership Schizophrenia-Aligned Project in Africa.肯尼亚精神病风险结果研究(KePROS):在非洲开展的一个与精神分裂症相关的加速医学伙伴项目的进展情况
Schizophr Bull Open. 2024 May 4;5(1):sgae009. doi: 10.1093/schizbullopen/sgae009. eCollection 2024 Jan.
9
Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: design considerations.加速药物合作组织精神分裂症项目中的体液生物标志物与精神病风险:设计考量
Schizophrenia (Heidelb). 2025 May 21;11(1):78. doi: 10.1038/s41537-025-00610-4.
10
The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures.加速药物合作组织精神分裂症项目的脑电图方案:测量的可靠性与稳定性
Schizophrenia (Heidelb). 2025 Jun 6;11(1):85. doi: 10.1038/s41537-025-00622-0.

本文引用的文献

1
Classifying and clustering mood disorder patients using smartphone data from a feasibility study.利用可行性研究中的智能手机数据对情绪障碍患者进行分类和聚类。
NPJ Digit Med. 2023 Dec 21;6(1):238. doi: 10.1038/s41746-023-00977-7.
2
Digital Phenotyping for Monitoring Mental Disorders: Systematic Review.数字表型监测精神障碍:系统评价。
J Med Internet Res. 2023 Dec 13;25:e46778. doi: 10.2196/46778.
3
Digital tools to support mental health: a survey study in psychosis.数字工具支持心理健康:精神病学中的一项调查研究。
BMC Psychiatry. 2023 Oct 7;23(1):726. doi: 10.1186/s12888-023-05114-y.
4
Implementing Technologies to Enhance Coordinated Specialty Care Framework: Implementation Outcomes From a Development and Usability Study.实施技术以加强协调专科护理框架:一项开发与可用性研究的实施成果
JMIR Form Res. 2023 Oct 3;7:e46491. doi: 10.2196/46491.
5
Methodological Characteristics and Feasibility of Ecological Momentary Assessment Studies in Psychosis: a Systematic Review and Meta-Analysis.精神病学中生态瞬时评估研究的方法学特征和可行性:系统评价和荟萃分析。
Schizophr Bull. 2024 Mar 7;50(2):238-265. doi: 10.1093/schbul/sbad127.
6
An exploratory analysis of the effect size of the mobile mental health Application, mindLAMP.移动心理健康应用程序mindLAMP效应量的探索性分析。
Digit Health. 2023 Jul 7;9:20552076231187244. doi: 10.1177/20552076231187244. eCollection 2023 Jan-Dec.
7
Returning Individual Research Results from Digital Phenotyping in Psychiatry.精神医学中数字化表型研究的个体研究结果回报。
Am J Bioeth. 2024 Feb;24(2):69-90. doi: 10.1080/15265161.2023.2180109. Epub 2023 May 8.
8
Long-term participant retention and engagement patterns in an app and wearable-based multinational remote digital depression study.一项基于应用程序和可穿戴设备的跨国远程数字抑郁症研究中的长期参与者保留率和参与模式。
NPJ Digit Med. 2023 Feb 17;6(1):25. doi: 10.1038/s41746-023-00749-3.
9
Relapse prediction in schizophrenia with smartphone digital phenotyping during COVID-19: a prospective, three-site, two-country, longitudinal study.COVID-19 期间使用智能手机数字表型分析预测精神分裂症复发:一项前瞻性、三中心、两国纵向研究
Schizophrenia (Heidelb). 2023 Jan 27;9(1):6. doi: 10.1038/s41537-023-00332-5.
10
Accelerating Medicines Partnership Schizophrenia (AMP SCZ): developing tools to enable early intervention in the psychosis high risk state.加速药物合作精神分裂症项目(AMP SCZ):开发工具以实现对精神病高危状态的早期干预。
World Psychiatry. 2023 Feb;22(1):42-43. doi: 10.1002/wps.21038.